Vivesto AB (Vivesto AB) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Vivesto AB Debt-to-Equity?

Vivesto AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Vivesto AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Vivesto AB's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $19.28 Mil. Vivesto AB's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vivesto AB's Debt-to-Equity or its related term are showing as below:

OASMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.36 Max: 0.56
Current: 0.03

During the past 13 years, the highest Debt-to-Equity Ratio of Vivesto AB was 0.56. The lowest was 0.02. And the median was 0.36.

OASMY's Debt-to-Equity is ranked better than
88.9% of 856 companies
in the Drug Manufacturers industry
Industry Median: 0.28 vs OASMY: 0.03

Vivesto AB Debt-to-Equity Historical Data

The historical data trend for Vivesto AB's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivesto AB Debt-to-Equity Chart

Vivesto AB Annual Data

Trend

Apr14

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.36

0.12

0.02

0.03

Vivesto AB Quarterly Data
	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.03	0.03	0.03	0.02	-

Competitive Comparison of Vivesto AB's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivesto AB's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vivesto AB's Debt-to-Equity falls into.

Vivesto AB Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vivesto AB's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	19.283
	=	0.00

Vivesto AB's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	19.283
	=	0.00

Vivesto AB (OTCPK:OASMY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vivesto AB Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vivesto AB's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivesto AB (Vivesto AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Vivesto AB (OTCPK:OASMY) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

VIVE:Sweden OMAX:Germany

Address

Gustav III:s Boulevard 46, 5th Floor, Solna, SWE, SE-169 73

Website

https://www.vivesto.com

Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.